Items Tagged with 'Alzheimer’s disease'

ARTICLES

Pfizer Trial Results Announced

On January 17, 2012, Medivation, Inc.(NASDAQ: MDVN) and Pfizer Inc. (NYSE: PFE) announced results from the CONCERT trial, which is a Phase 3 trial that evaluated dimebon (latrepirdine) when added to ongoing treatment with donepezil HCL tablets in patients with mild-to-moderate Alzheimer’s disease.


Read More

Your Financial Security is Serious Business...

so why should you trust The Turnaround Letter?

  • Ranked #1 for 15-Yr. Annualized Returns: Turnaround Letter's 13.2% vs. S&P's 2.2%
  • 28+ Years of Turnaround Investing Experience & Reliable Stock Market Advice
  • Diverse Monthly Stock Picks Personally Selected by George Putnam

Distressed Investing Blog

Distressed Investing Blog

Looking for a Year-End Bounce: Stock Profit from Artificial Selling Pressures

Looking to cash in on timely tax loss selling and portfolio window dressing? These 10 year-end bounce stock picks represent the worst performers in the S&P 500 during calendar 2014, adjusted somewhat so that there is good diversification by industry group. Read More.

Sample Issue

TL Spotlight

George Putnam has always followed the same straight-forward and highly-profitable investment philosophy. He published his first Turnaround Letter issue back in 1986, and readers have seen extraordinary long-term stock profit ever since.

 

In fact, 12 of 2014's 13 closed-out purchase recommendations saw gains--with five of those enjoying total returns greater than 100%. The Turnaround Letter's average return for 2014's stock picks is +82%:

 

2014 Closed Out Purchase Recommendations

Value Stock Picks

* Calculation includes dividends and price changes between purchase recommendation and current price.

 

Learn more.